Updated 5.5.2006
Senior Physician
Department of Oncology
Hadassah University Hospital
Ein-Karem, Jerusalem.
Telephone: 972-2-5662974
e-mail: lunak99@yahoo.com
Nationality: Israeli
Date of Birth: 8.5.1963
Status: Married + 2 children
Address: 2, Aluf Simhoni, Jerusalem. 92504
Education
1984-1990 M.D.- Hadassah University Medical School, Jerusalem, Israel
Licensing
1995 - Board exam in Radiation and Medical Oncology, Stage I
1996 - Board exam in Radiation and Medical Oncology, Stage II
1998 - ECFMG – US licensing exam
Research and Professional Experience:
1990-1991 Intern, Hadassah University Hospital
1992-1997 Resident, Oncology Dept. Hadassah University Hospital
1997-1998 Senior Physician, Oncology Dept. Hadassah University Hospital
1998-2000 Clinical & research fellowship, Royal Marsden Hospital and Institute of Cancer Research, England
§ Family cancer risk clinic, director Dr Rosalind A. Eeles:
§ Risk assesment for patients with strong family history of breast, ovarian and colon cancer.
§ Research in the cancer genetic Laboratory of Dr Rosalind A. Eeles.
§ Project: Low penetrant modiffiers genes and breast cancer susceptibility in population of BRCA1/2 carriers and non-carriers.
2000-todate Senior Physician, Oncology Dept., Hadassah University Hospital.
Grants
1995 Israel Cancer Research Association, 10,000NIS.
2000 Women’s health grant for returning physicians, 25,000$.
Awards
1. The Landau Family Prize for Oncology Research, 1997
2. Hadassah Research Fund Award for Cancer Genetic Research, 1998
3. Barclay Fund award for clinical and research fellowship in oncology through the British Councilm 1998-2000
4. Prize in memory of Jehudith Segal for Cancer Research, 2001
Memberships in Professional Associations
§ Member of the Israel Society of Clinical Oncology
§ Member of the Israel Medical Society
Academic Experience
1995-1997 Instructor, Medical/Radiation Oncology, Hebrew University, Jerusalem. Tutor for interns research thesis:
2000 - The prevalence of the BRCA2 mutation 8765 del AG in Yemenite Jews. By Dr Nemirovsky
2001 - The role of SULT1A1 in breast cancer risk in BRCA1/2 carriers. By Dr Rosenbaum
2001 - The contribution of BRCA1/2 Ashkenazi mutations to melanoma incidence
in the Ashkenazi population. By Dr Temper
Teaching Experience
1993-1997Physical examination for 4th year medical students
2001Teaching for 5th year medical students (lectures, bed side teaching)
1997-8 and 2000-1 Teaching for residents and fellows (lectures and bed side teaching)
Publications
Original research papers
Sagi, M., Heching, N., Kadouri, L., Abeliovich, D., Zlotogora, J., Bach, G., Peretz, T.: Genetic counselling for families at high cancer risk. Harefuah 130:441-446, 1996.
Abeliovich, D., Kaduri, L., Lerer, I., Wienberg, N., Amir, G., Sagi, M., Zlotogora, J., Peretz, T.: The founder mutations 185delAG and 5382insC in the BRCA1 and 6174delT in BRCA2 apear in 60% of ovarian cancer and 30% of early onset breast cancer patients among Ashkenazi women. Am. J. Hum. Genet.: 60:505-514, 1997.
Sagi, M., Kaduri, L., Zlotogora, J., Peretz, T.: The effect of genetic counseling on knowledge and receptions regarding risks for breast cancer. Accepted to Genet Couns.
Lerer, I., Teiling, W., Peretz, T., Sagi, M., Kaduri, L., Orr-Urteger, A., Stadler, J., Gutman, H., Abeliovich, D.: The 8765delAG mutation in BRCA2 is common among jews of Yemenite extraction. Am J Hum Genet: 63 (1): 272-274, 1998.
Kaduri, L., Gips, M., Hubert, A., Sagi, M., Heching N., Lerer, I., Uziely, B., Wienberg, N., Abeliovich, D., Peretz, T.: Genetic testing of breast and ovarian cancer patients: Clinical caracteristics and hormonal risk modifiers. Eur J Obstet Gynecol Reprod Biol, 85 (1): 75-80, 1999.
Wang T., Lerer, I., Peretz, T., Sagi, M., Kaduri, L., Hubert, A., Abeliovich, D.: A BRCA2 mutation 8558delA in an Ashkenazi breast cancer patient. Hum Mut, 12:291. 1998
Hubert, A., Peretz, T., Manor, O., Kaduri, L., Wienberg, N., Lerer, I., Sagi, M., Abeliovich, D.: The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased friquency in Ashkenazi patients with prostate cancer. Am J Hum Genet, 65 (3): 921-924, 1999.
Barak V., Nisman B., Hubert A., Lyass O., Kaduri L., Peretz T.: Prognostic efficacy of TPS in breast cancer. J Tum Mark Oncol, 15 (3): 171-176, 2000.
Wang T., Lerer I., Gueta Z., Sagi M., Kadouri L., Peretz T., Abeliovich D.: A deletion/insertion mutation in BRCA2 gene in a breast cancer family: A possible role of the Alu-polyA tail in the evolution of the deletion. Gene, Chromosome & Cancer, 2001; 31(1): 91-5
Kadouri L., Easton DF., Edwards S., Hubert A., Kote-Jarai Z., Glaser B., Durocher F., Abeliovich D., Peretz T., Eeles RA.: CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer, 2001 85(1): 36-40
Paltiel O., Avitzour M., Peretz T., Cherny N., Kaduri L., Pfeffer RM., Wagner N., Soskolne V.: Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol, 2001 19(9): 2439-48
Rennert H., Bercovich D., Hubert A, Abeliovich D., Rozovsky U., Bar Shira A., Soloviov S., Schreiber L., Matzkin H., Rennert G., Kadouri L., Peretz T., Yaron Y., Orr-Urteger A. A novel founder mutation in the RNASEL gene, 471delAAAG is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002, Jul 23 (epub ahead of print).
Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, Peretz T, Mandelboim O, Ben-Yehuda D. Caspase-mediated cleavage converts Livin from antiapoptotic to a proapoptotic factor. Implications for drug resistant melanoma. Cancer Res 2003, 63(19): 6340-9.
Lotem M, Shiloni E, Pappo I, Dirize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 2004, 90(4): 773-80.
Kadouri L, Kote-Jarai Z, Easton EF, Hubert A, Hanoudi R, Glaser B, Abeliovich D, Peretz T, Eeles RA. Polyglutamine repeat length in the AIB! Gene modifies breast cancer suscptibility in BRCA1 carriers. Int J Cancer 2004, 108: 399-403.
Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, Peretz T. A single nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers and non-Carriers. Br J Cancer 2004, 90 (10): 2002-5
17. Orr-Urteger A, Bae Shira A, Bercovich D, Matarasso N, Rozovsky J, Rosner S, Soloviov S, Rennert G, Kadouri L, Hubert A, Rennert H, Matzkin H. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidem Biom Prev 2006, 15 (3): 474-9.
More in PubMed
Reviews
Kadouri, L., Heching, N., Abeliovich, D., Peretz, T.: Inherited breast cancer. Harefua: 131:418-421, 1996.
Eeles, R., Kadouri, L.: BRCA1/2 carriers and endocrine risk modifiers. Endocrine Related Cancer, 6 (4): 521-528, 1999